(9ci)-3-氨基-1-环戊烯-1-羧酸 | 74201-88-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (9ci)-3-氨基-1-环戊烯-1-羧酸
• 英文名称: 3-aminocyclopent-1-ene-1-carboxylic acid
• 英文别名: 3-aminocyclopentene-1-carboxylic acid
• CAS: 74201-88-0
• 化学式: C₆H₉NO₂
• mdl: MFCD18806845
• 分子量: 127.143
• InChiKey: RQYHWGCBMDDOAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (9ci)-3-氨基-1-环戊烯-1-羧酸 在 palladium on activated charcoal 盐酸 、 氢气 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 5.0~25.0 ℃ 、405.3 kPa 条件下， 反应 8.0h， 生成 trans-3-aminocyclopentane-1-carboxylic acid
  参考文献：
  名称：

  Synthesis of analogues of GABA. IV. Three unsaturated derivatives of 3-aminocyclopentane-1-carboxylic acid

  摘要：

  顺式-4-氨基环戊-2-烯-1-羧酸 (4)、4-氨基环戊-1-烯-1-羧酸 (5) 酸 (4)、4-氨基环戊-1-烯-1-羧酸 (5) 和 3-氨基环戊-1-烯-1-羧酸 (6) 作为构象受限的类似物被合成。 3-aminocyclopent-1-ene-1-carboxylic acid (6) 已被合成为抑制性神经递质 GABA 的构象受限类似物。 神经递质 GABA 的构象受限类似物。

  DOI：

  10.1071/ch9800599
• 作为产物：
  描述：

  3-bromocyclopent-1-enecarbonitrile 在 氨 作用下， 以 乙醚 为溶剂， 反应 1.33h， 生成 (9ci)-3-氨基-1-环戊烯-1-羧酸
  参考文献：
  名称：

  Synthesis of analogues of GABA. IV. Three unsaturated derivatives of 3-aminocyclopentane-1-carboxylic acid

  摘要：

  顺式-4-氨基环戊-2-烯-1-羧酸 (4)、4-氨基环戊-1-烯-1-羧酸 (5) 酸 (4)、4-氨基环戊-1-烯-1-羧酸 (5) 和 3-氨基环戊-1-烯-1-羧酸 (6) 作为构象受限的类似物被合成。 3-aminocyclopent-1-ene-1-carboxylic acid (6) 已被合成为抑制性神经递质 GABA 的构象受限类似物。 神经递质 GABA 的构象受限类似物。

  DOI：

  10.1071/ch9800599

文献信息

• ALLAN R. D.; TWITCHIN B., AUSTRAL. J. CHEM., 1980, 33, NO 3, 599-604
  作者：ALLAN R. D.、 TWITCHIN B.

  DOI：——

  日期：——
• 3-AMINO-4-HALOCYCLOPENTENE CARBOXYLIC ACIDS AS INACTIVATORS OF AMINOTRANSFERASES
  申请人：Northwestern University

  公开号：US20210238120A1

  公开（公告）日：2021-08-05

  Disclosed are cyclopentene compounds for use as inhibitors of aminotransferases such as gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-amino-4-halocyclopente carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC).
• [EN] METHODS AND SYSTEMS FOR MODULATING HEPATIC GABA PRODUCTION OR RELEASE TO ALTER FOOD INTAKE IN MONOGASTRIC SPECIES<br/>[FR] PROCÉDÉS ET SYSTÈMES POUR MODULER LA PRODUCTION OU LA LIBÉRATION DE GABA HÉPATIQUE POUR MODIFIER L'APPORT ALIMENTAIRE CHEZ DES ESPÈCES MONOGASTRIQUES
  申请人：UNIV ARIZONA

  公开号：WO2021062048A2

  公开（公告）日：2021-04-01

  Methods and compositions (such as compounds, drugs, molecules, etc,) for modulating food intake, e.g., increasing food intake or reducing food intake, in a monogastric animal species. Certain methods herein feature administering to the animal a composition that depresses hepatic GABA production, depresses GABA release, inhibits expression or activity of GABA transaminase, inhibits expression or activity of particular GABA transporters associated with export of GABA, increases expression or activity of particular GABA transporters associated with GABA re- uptake, etc. The methods may help decrease food intake and subsequently improve weight loss. Certain methods herein may feature administering to the animal a composition that activates hepatic GABA production, activates GABA release, increases expression or activity of GABA transaminase, increases expression or activity of particular GABA transporters associated with export of GABA, decreases expression or activity of particular GABA transporters associated with GABA re-uptake, etc. The methods may help increase food intake, and subsequently help promote weight gain.
• [EN] METHODS AND COMPOSITIONS TO ALTER HEPATIC GABA RELEASE TO TREAT OBESITY-RELATED CONDITIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR MODIFIER LA LIBÉRATION DE GABA HÉPATIQUE POUR TRAITER DES PROBLÈMES DE SANTÉ LIÉS À L'OBÉSITÉ
  申请人：UNIV ARIZONA

  公开号：WO2021203033A2

  公开（公告）日：2021-10-07

  Methods and compositions for treating conditions caused by altered hepatic GABA production and release, including hyperinsulinemia, insulin resistance, type II diabetes, obesity, and obesity-related conditions. The present invention describes hepatic GABA as a hepatokine. The methods herein feature manipulating the expression and/or activity of specific GABA transporters, e.g., increasing expression of SLC6A12 and/or SLC6A13 genes or increasing activity of the proteins for which they encode, BGT1 and/or GAT2; or decreasing expression of SLC6A6 and SLC6A8 genes or increasing the activity of the proteins for which they encode, TauT and/or CRT, which can increase hepatic GABA re-uptake or decrease hepatic GABA release to improve insulin sensitivity and prevent hypertension.
• Synthesis of analogues of GABA. IV. Three unsaturated derivatives of 3-aminocyclopentane-1-carboxylic acid
  作者：RD Allan、B Twitchin

  DOI：10.1071/ch9800599

  日期：——

  cis-4-Aminocyclopent-2-ene-1-carboxylic acid (4), 4-aminocyclopent-1- ene-1-carboxylic acid (5) and 3-aminocyclopent-1-ene-1-carboxylic acid (6) have been synthesized as conformationally restricted analogues of the inhibitory neurotransmitter GABA.

  顺式-4-氨基环戊-2-烯-1-羧酸 (4)、4-氨基环戊-1-烯-1-羧酸 (5) 酸 (4)、4-氨基环戊-1-烯-1-羧酸 (5) 和 3-氨基环戊-1-烯-1-羧酸 (6) 作为构象受限的类似物被合成。 3-aminocyclopent-1-ene-1-carboxylic acid (6) 已被合成为抑制性神经递质 GABA 的构象受限类似物。 神经递质 GABA 的构象受限类似物。